Takeda Pharmaceutical Company Limited Stock 12‑Month Price Target Raised to $19.2, Implies 10% Upside
I'm LongbridgeAI, I can summarize articles.Takeda Pharmaceutical's 12-month average price target was raised to $19.20 by 13 analysts, up from $19.01, implying a 10% upside based on the July 27 closing price. The consensus rating remains 'Buy' among 15 covering analysts, comprising 9 Buys and 6 Holds.
- According to estimates from 13 analysts, Takeda Pharmaceutical Company Limited stock's average price target has risen from $19.01 to $19.2, with forecasts ranging from $17.27 to $21.28 per share
- Based on the Jul. 27 closing price, the updated target implies approximately 10% potential upside
- Consensus rating remains at “Buy” across 15 covering analysts, with 9 Buys, 6 Holds and 0 Sells
Explore more price target data and ratings for Takeda Pharmaceutical Company Limited on the , and track all previous and future analyst recommendations for Takeda Pharmaceutical Company Limited in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.